Cargando…
Results from a large targeted screening program for alpha-1-antitrypsin deficiency: 2003 - 2015
BACKGROUND: Alpha-1-antitrypsin deficiency (AATD) is an autosomal codominant inherited disease that is significantly underdiagnosed. We have previously shown that the combination of an awareness campaign with the offer of free diagnostic testing results in the detection of a relevant number of sever...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4901499/ https://www.ncbi.nlm.nih.gov/pubmed/27282198 http://dx.doi.org/10.1186/s13023-016-0453-8 |
_version_ | 1782436817758322688 |
---|---|
author | Greulich, Timm Nell, Christoph Herr, Christian Vogelmeier, Claus Kotke, Viktor Wiedmann, Stefan Wencker, Marion Bals, Robert Koczulla, Andreas Rembert |
author_facet | Greulich, Timm Nell, Christoph Herr, Christian Vogelmeier, Claus Kotke, Viktor Wiedmann, Stefan Wencker, Marion Bals, Robert Koczulla, Andreas Rembert |
author_sort | Greulich, Timm |
collection | PubMed |
description | BACKGROUND: Alpha-1-antitrypsin deficiency (AATD) is an autosomal codominant inherited disease that is significantly underdiagnosed. We have previously shown that the combination of an awareness campaign with the offer of free diagnostic testing results in the detection of a relevant number of severely deficient AATD patients. The present study provides an update on the results of our targeted screening program (German AAT laboratory, University of Marburg) covering a period from August 2003 to May 2015. METHODS: Diagnostic AATD detection test kits were offered free of charge. Dried blood samples were sent to our laboratory and used for the semiquantitative measurement of the AAT-level (nephelometry) and the detection of the S- or Z-allele (PCR). Isoelectric focusing was performed when either of the initial tests was indicative for at least one mutation. Besides, we evaluated the impact of additional screening efforts and the changes of the detection rate over time, and analysed the relevance of clinical parameters in the prediction of severe AATD. RESULTS: Between 2003 and 2015, 18,638 testing kits were analysed. 6919 (37.12 %) carried at least one mutation. Of those, we identified 1835 patients with severe AATD (9.82 % of the total test population) including 194 individuals with rare genotypes. Test initiatives offered to an unselected population resulted in a dramatically decreased detection rate. Among clinical characteristics, a history of COPD, emphysema, and bronchiectasis were significant predictors for Pi*ZZ, whereas a history of asthma, cough and phlegm were predictors of not carrying the genotype Pi*ZZ. CONCLUSION: A targeted screening program, combining measures to increase awareness with cost-free diagnostic testing, resulted in a high rate of AATD detection. The clinical data suggest that testing should be primarily offered to patients with COPD, emphysema, and/or bronchiectasis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13023-016-0453-8) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4901499 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-49014992016-06-11 Results from a large targeted screening program for alpha-1-antitrypsin deficiency: 2003 - 2015 Greulich, Timm Nell, Christoph Herr, Christian Vogelmeier, Claus Kotke, Viktor Wiedmann, Stefan Wencker, Marion Bals, Robert Koczulla, Andreas Rembert Orphanet J Rare Dis Research BACKGROUND: Alpha-1-antitrypsin deficiency (AATD) is an autosomal codominant inherited disease that is significantly underdiagnosed. We have previously shown that the combination of an awareness campaign with the offer of free diagnostic testing results in the detection of a relevant number of severely deficient AATD patients. The present study provides an update on the results of our targeted screening program (German AAT laboratory, University of Marburg) covering a period from August 2003 to May 2015. METHODS: Diagnostic AATD detection test kits were offered free of charge. Dried blood samples were sent to our laboratory and used for the semiquantitative measurement of the AAT-level (nephelometry) and the detection of the S- or Z-allele (PCR). Isoelectric focusing was performed when either of the initial tests was indicative for at least one mutation. Besides, we evaluated the impact of additional screening efforts and the changes of the detection rate over time, and analysed the relevance of clinical parameters in the prediction of severe AATD. RESULTS: Between 2003 and 2015, 18,638 testing kits were analysed. 6919 (37.12 %) carried at least one mutation. Of those, we identified 1835 patients with severe AATD (9.82 % of the total test population) including 194 individuals with rare genotypes. Test initiatives offered to an unselected population resulted in a dramatically decreased detection rate. Among clinical characteristics, a history of COPD, emphysema, and bronchiectasis were significant predictors for Pi*ZZ, whereas a history of asthma, cough and phlegm were predictors of not carrying the genotype Pi*ZZ. CONCLUSION: A targeted screening program, combining measures to increase awareness with cost-free diagnostic testing, resulted in a high rate of AATD detection. The clinical data suggest that testing should be primarily offered to patients with COPD, emphysema, and/or bronchiectasis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13023-016-0453-8) contains supplementary material, which is available to authorized users. BioMed Central 2016-06-10 /pmc/articles/PMC4901499/ /pubmed/27282198 http://dx.doi.org/10.1186/s13023-016-0453-8 Text en © Greulich et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Greulich, Timm Nell, Christoph Herr, Christian Vogelmeier, Claus Kotke, Viktor Wiedmann, Stefan Wencker, Marion Bals, Robert Koczulla, Andreas Rembert Results from a large targeted screening program for alpha-1-antitrypsin deficiency: 2003 - 2015 |
title | Results from a large targeted screening program for alpha-1-antitrypsin deficiency: 2003 - 2015 |
title_full | Results from a large targeted screening program for alpha-1-antitrypsin deficiency: 2003 - 2015 |
title_fullStr | Results from a large targeted screening program for alpha-1-antitrypsin deficiency: 2003 - 2015 |
title_full_unstemmed | Results from a large targeted screening program for alpha-1-antitrypsin deficiency: 2003 - 2015 |
title_short | Results from a large targeted screening program for alpha-1-antitrypsin deficiency: 2003 - 2015 |
title_sort | results from a large targeted screening program for alpha-1-antitrypsin deficiency: 2003 - 2015 |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4901499/ https://www.ncbi.nlm.nih.gov/pubmed/27282198 http://dx.doi.org/10.1186/s13023-016-0453-8 |
work_keys_str_mv | AT greulichtimm resultsfromalargetargetedscreeningprogramforalpha1antitrypsindeficiency20032015 AT nellchristoph resultsfromalargetargetedscreeningprogramforalpha1antitrypsindeficiency20032015 AT herrchristian resultsfromalargetargetedscreeningprogramforalpha1antitrypsindeficiency20032015 AT vogelmeierclaus resultsfromalargetargetedscreeningprogramforalpha1antitrypsindeficiency20032015 AT kotkeviktor resultsfromalargetargetedscreeningprogramforalpha1antitrypsindeficiency20032015 AT wiedmannstefan resultsfromalargetargetedscreeningprogramforalpha1antitrypsindeficiency20032015 AT wenckermarion resultsfromalargetargetedscreeningprogramforalpha1antitrypsindeficiency20032015 AT balsrobert resultsfromalargetargetedscreeningprogramforalpha1antitrypsindeficiency20032015 AT koczullaandreasrembert resultsfromalargetargetedscreeningprogramforalpha1antitrypsindeficiency20032015 |